» Articles » PMID: 16585430

Recent Trends in Stimulant Medication Use Among U.S. Children

Overview
Journal Am J Psychiatry
Specialty Psychiatry
Date 2006 Apr 6
PMID 16585430
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Stimulant medications, such as methylphenidate and amphetamines, are commonly prescribed to treat attention deficit hyperactivity disorder. Stimulant use increased fourfold from 1987 (0.6%) to 1996 (2.4%) among subjects 18-year-old and younger in the U.S. The aim of this study was to determine whether pediatric use of stimulants continued to rise during the period 1997-2002.

Method: The Medical Expenditure Panel Survey (MEPS) database for the years 1997-2001 was analyzed. The MEPS is a yearly survey of a nationally representative sample of civilian, noninstitutionalized U.S. households, conducted by the U.S. Agency for Health Care Research and Quality. Previously reported estimates from the 1996 MEPS and the 1987 National Medical Expenditure Survey, the predecessor to MEPS, were also replicated to compare recent trends to changes between 1987 and 1996.

Results: The prevalence use of stimulants among subjects under 19 years of age was 2.7% (95% C.I. 2.3-3.1) in 1997 and 2.9% (95% C.I. 2.5-3.3) in 2002, with no statistically significant change during these 6 years. Likewise, when pooling data across years and comparing the rate in 1997-1998 (2.8%) with the rate in 2001-2002 (3.0%), no statistically significant changes emerged. Use was highest among 6-12 year olds (4.8% in 2002), as compared with 3.2% among 13-19 year olds and 0.3% among children under 6. An estimated 2.2 million (95% C.I. 1.9-2.6) children received stimulant medication in 2002 as compared to 2.0 million (95% C.I. 1.7-2.3) in 1997.

Conclusions: The steep increase in the utilization of stimulants among children 18 years and younger that occurred over the 1987-1996 period attenuated in the following years through 2002, and has remained stable among very young children.

Citing Articles

Patterns of Medication Prescription among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in the United States.

Meraya A Children (Basel). 2022; 9(2).

PMID: 35204892 PMC: 8870051. DOI: 10.3390/children9020171.


Diagnostic and Medication Treatment Disparities in African American Children with ADHD: a Literature Review.

Glasofer A, Dingley C J Racial Ethn Health Disparities. 2021; 9(5):2027-2048.

PMID: 34520001 DOI: 10.1007/s40615-021-01142-0.


Overdiagnosis of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Systematic Scoping Review.

Kazda L, Bell K, Thomas R, McGeechan K, Sims R, Barratt A JAMA Netw Open. 2021; 4(4):e215335.

PMID: 33843998 PMC: 8042533. DOI: 10.1001/jamanetworkopen.2021.5335.


Acute Physical Activity, Executive Function, and Attention Performance in Children with Attention-Deficit Hyperactivity Disorder and Typically Developing Children: An Experimental Study.

Miklos M, Komaromy D, Futo J, Balazs J Int J Environ Res Public Health. 2020; 17(11).

PMID: 32517384 PMC: 7312258. DOI: 10.3390/ijerph17114071.


Methylphenidate and Guanfacine Ameliorate ADHD-Like Phenotypes in -Deficient Mice.

Sumitomo A, Saka A, Ueta K, Horike K, Hirai K, Gamo N Mol Neuropsychiatry. 2018; 3(4):223-233.

PMID: 29888233 PMC: 5981631. DOI: 10.1159/000488081.